Shares of Sarepta Therapeutics fell after the biotech company said that one of its experimental gene-replacement therapies was linked to the death of a 51-year-old man last month. Shares, which lost ...

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Wall Street awaits earnings Monday from Verizon.